Verition Fund Management LLC Invests $709,000 in Genmab A/S (NASDAQ:GMAB)

Verition Fund Management LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 29,074 shares of the company's stock, valued at approximately $709,000.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its holdings in Genmab A/S by 123.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company's stock valued at $81,000 after buying an additional 1,787 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock worth $108,000 after acquiring an additional 3,880 shares during the period. Headlands Technologies LLC increased its stake in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock valued at $129,000 after purchasing an additional 4,853 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock worth $182,000 after purchasing an additional 478 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new position in Genmab A/S during the third quarter worth $192,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Down 1.3 %

Shares of GMAB stock traded down $0.28 on Tuesday, reaching $21.83. 985,440 shares of the stock were exchanged, compared to its average volume of 733,844. Genmab A/S has a 1-year low of $20.34 and a 1-year high of $32.88. The stock has a market cap of $14.45 billion, a P/E ratio of 21.33, a price-to-earnings-growth ratio of 0.68 and a beta of 0.96. The firm has a 50 day moving average of $22.36 and a two-hundred day moving average of $25.24.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the prior year, the firm earned $0.47 earnings per share. On average, equities research analysts predict that Genmab A/S will post 1.29 EPS for the current fiscal year.

Analyst Ratings Changes

GMAB has been the subject of a number of research analyst reports. Redburn Atlantic assumed coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a "buy" rating for the company. Morgan Stanley restated an "equal weight" rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. Truist Financial reduced their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, September 9th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 16th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a research report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.